Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.

Autor: Villalba-López F; Murcia's BioHealth Research Institute, IMIB-Arrixaca, 30120, Murcia, Spain. curro_villalba_lopez@hotmail.com., Sáenz-Mateos LF; Division of Clinical Biochemistry, University Hospital Rafael Méndez, 30813, Lorca, Spain., Sánchez-Lorencio MI; Murcia's BioHealth Research Institute, IMIB-Arrixaca, 30120, Murcia, Spain., De La Orden-García V; Genetracer Biotech, 28942, Fuenlabrada, Spain., Alconchel-Gago F; Liver Transplant Unit, University Hospital Virgen de la Arrixaca, 30120, Murcia, Spain., Cascales-Campos PA; Liver Transplant Unit, University Hospital Virgen de la Arrixaca, 30120, Murcia, Spain., García-Bernardo C; Liver Transplant Unit, Asturias University Hospital, 33011, Oviedo, Spain., Noguera-Velasco JA; Division of Clinical Biochemistry, University Hospital Virgen de la Arrixaca, 30120, Murcia, Spain., Baroja-Mazo A; Murcia's BioHealth Research Institute, IMIB-Arrixaca, 30120, Murcia, Spain., Ramírez-Romero P; Liver Transplant Unit, University Hospital Virgen de la Arrixaca, 30120, Murcia, Spain.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Apr 06; Vol. 13 (1), pp. 5621. Date of Electronic Publication: 2023 Apr 06.
DOI: 10.1038/s41598-023-32879-9
Abstrakt: The high morbidity and mortality of hepatocellular carcinoma (HCC) has encouraged the search for new biomarkers to be used alongside alpha-foetoprotein (AFP) and imaging tests. The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence or antagonist-II (PIVKA-II) for HCC monitoring after liver transplantation (LT) and compare it with AFP, a routinely used tumour marker. A total of 46 HCC patients (Milan criteria) were enrolled in this study. Serum levels of PIVKA-II and AFP were measured before and after transplantation. Clinical features were determined for all the patients that were included. Significant correlations were found between PIVKA-II expression levels and some clinicopathological features, such as tumour size and number of pre-transplant transarterial chemoembolizations (TACEs). Serum levels of PIVKA-II and AFP decreased significantly after LT and increased in patients with tumour recurrence. Serum PIVKA-II levels may play an important role in predicting disease severity. Furthermore, monitoring PIVKA-II levels in HCC transplant recipients reflects the tumor early recurrence after transplantation and could be used, complementing AFP and imaging tests, as a novel biomarker of this pathology.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje